As Adult Autism Diagnoses Surge, The Care Gap Grows – Here's How One Company Is Fixing It
Founded in 2023 by two neurodivergent women, NeuroSpark Health has helped thousands of adults gain clarity and self-understanding through virtual ADHD and autism assessments. While many providers still rely on outdated diagnostic models, NeuroSpark Health takes a different approach—one that recognizes the unique ways autism and ADHD present in adults, particularly those who have masked traits for years. Furthermore, lived experience is an integral aspect of their model. Dani Rodwell, co-founder of NeuroSpark Health, says ' Our clients feel safe and comfortable knowing that every single one of our providers are themselves autistic, ADHD, or both. Lived experience matters.'
"Many of our clients have spent their whole lives wondering if they might be autistic or have ADHD, only to be dismissed by professionals or unable to access care," says Dr. Julie Landry, co-founder of NeuroSpark Health. 'As we celebrate two years in business, our mission remains the same: to provide adults with the affirming, accessible, and expert-led assessments they deserve.'
The Future of Neurodivergent Healthcare
NeuroSpark Health is leading the future of adult autism and ADHD assessments by:
Providing fully virtual evaluations across 45 states, making evaluations more accessible nationwide
Using neurodiversity-affirming frameworks instead of pathologizing approaches
Addressing the unique diagnostic challenges of late-identified, high-masking adults
Providing affirming care for queer, trans, and BIPOC individuals who have historically been underdiagnosed or misdiagnosed
As awareness of neurodivergence continues to grow, so does the urgency for accessible, high-quality assessments that serve neurodivergent adults. With an entire community of adults still undiagnosed and seeking clarity, the need for innovative, affirming healthcare solutions has never been greater.
NeuroSpark Health is proud to celebrate two years of meeting this need—and revolutionizing care for the autistic and ADHD community.
For media inquiries, interviews, or additional information, contact: info@neurosparkhealth.com
Media Contact
Company Name: NeuroSpark Health
Contact Person: Dani Rodwell
Email: Send Email
City: Maplewood
State: NJ
Country: United States
Website: https://www.neurosparkhealth.com/
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
7 hours ago
- Cision Canada
Kye Pharmaceuticals Announces the Approval of DYANAVEL® XR (amphetamine extended-release) Tablets and Oral Suspension for the Treatment of Adults and Children With ADHD Français
MISSISSAUGA, ON, Aug. 5, 2025 /CNW/ - Kye Pharmaceuticals Inc. ("Kye"), a leading Canadian-based commercial-stage specialty pharmaceutical company focused on licensing and commercializing innovative medicines for patients in Canada, is pleased to announce the Health Canada approval (notice of compliance) for Dyanavel ® XR (amphetamine extended-release) tablets and oral suspension. Dyanavel ® XR is indicated for the treatment of ADHD in adults 18 years of age and over as well as in children aged 6-12 years old. 1 Dyanavel ® XR is a long-acting psychostimulant. These types of treatments for ADHD are recommended as first line by the Canadian ADHD resource alliance (CADDRA) guidelines. 2 Attention Deficit Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental disorder leading to impairments in learning and behaviour. ADHD affects approx. 3-5% of adults and 5-9% of children and adolescents 3. Patients with ADHD experience difficulties regulating their attention or focus. Dr. Sam Chang MD, FRCPC, Child and Adolescent Psychiatrist, Clinical Associate Professor, University of Calgary "ADHD is a complex neuro-developmental condition. The goal of treatment is having the patient realize their full potential. Dyanavel ® XR will provide an important new option for HCPs to optimize ADHD treatment in Adults and Children." Dr. Ghalib Ahmed MD, CCFP,FCFP, Assistant Clinical Professor-University of Alberta, Faculty of Medicine, General Practitioner-Chokka Centre, Secretary- CADDRA Board "Every person and family affected by ADHD deserves access to treatment options that reflect their unique journeys, needs, challenges, and goals." John McKendry, President and CEO of Kye Pharmaceuticals "Dyanavel ® XR, developed using the novel LiquiXR ® extended-release delivery technology is the first and only extended-release oral suspension and chewable tablet amphetamine approved in Canada. Alongside our recent launches of Quillivant ® ER Oral Suspension and Chewable Tablets, our team has the privilege of supporting the most extensive portfolio of branded ADHD medicines in Canada." About ADHD ADHD is a chronic neurodevelopmental disorder leading to impairments in learning and behaviour. ADHD affects approx. 3-5% of adults and 5-9% of children and adolescents 3. Patients with ADHD experience difficulties regulating their attention or focus. According to the Centre for ADHD Awareness, Canada (CADDAC), 50-80% of children diagnosed with ADHD continue to qualify for a diagnosis in adolescence and at least 65% continue to be impaired by symptoms in adulthood. 3,4 About Dyanavel ® XR - Tablets and Oral suspension Dyanavel ® XR (amphetamine, extended-release) - Tablet and Oral suspension is approved in Canada for the treatment of ADHD in children six to 12 years of age as well as in adults over the age of 18. The onset of action is significant at one hour post dose with a duration of therapy of 13 hours for both formulations. 1 DYANAVEL ® XR has a tablet and oral suspension formulations that use a drug delivery technology called LiquiXR ® made up of resin bound uncoated immediate-release drug and extended-release drug with variable coating. The combination of free drug, resin-bound uncoated drug and resin bound coated drug with variable thickness coating results in continuous release of amphetamine. This technology was developed by Tris Pharma. Dyanavel ® XR tablets can be chewed or swallowed. About Kye Pharmaceuticals Kye, headquartered in Toronto, is a leading growth-stage Canadian specialty pharmaceutical company committed to bringing value to Canadians by identifying, licensing, and commercializing novel prescription medicines that may not otherwise be available to patients across Canada. With a growing pipeline of innovative medicines, Kye's portfolio spans a range of therapeutic areas including cardiology, psychiatry, pediatrics, rare diseases, neuromuscular, hematology, and neurology. Kye Pharmaceuticals is a private company, founded in Canada and focused exclusively on the healthcare needs of patients in Canada. Kye aims to provide medicines that deliver better outcomes to our partners, Canadian healthcare professionals, and most importantly, patients across Canada. For more information, please visit Dyanavel XR (amphetamine extended-release) Oral Suspension and Tablets. Product Monograph. Kye Pharmaceuticals Inc., Mississauga, ON. CADDRA - Canadian ADHD Resource Alliance: Canadian ADHD Practice Guidelines, 4.1 Edition, Toronto ON; CADDRA, 2020. Available at (Accessed July 2025) (Accessed July 2025) (Accessed July 2025) SOURCE Kye Pharmaceuticals Inc.
Cision Canada
23-07-2025
- Cision Canada
British Columbia Joins Other Provincial Public Drug Plans Now Reimbursing FOQUEST® on their Formulary for Attention Deficit Hyperactivity Disorder (ADHD)
TORONTO, July 23, 2025 /CNW/ - Elvium Life Sciences is pleased to announce the addition of FOQUEST ® (methylphenidate hydrochloride controlled release capsules) to the British Columbia 1 PharmaCare formulary and First Nations Health Authority (FNHA) Pharmacy Benefit. With provincial funding in place in British Columbia, FOQUEST ® is now reimbursed from coast to coast on all provincial drug plans across Canada. "Public funding in British Columbia ensures equitable access to ADHD treatments in BC," said Juanita Beaudry, Executive Director of the Centre for ADHD Awareness (CADDAC) "This latest approval now provides access across Canada to another treatment option for patients." British Columbia now joins Alberta 2, Saskatchewan 3, Manitoba 4, Ontario 5, Quebec 6, Atlantic Canada 7,8,9,10, the Non-Insured Health Benefit Plan 11 and Correctional Service Canada in providing public formulary coverage for FOQUEST ® for the treatment of ADHD in patients aged six years and older. "Elvium Life Sciences is very pleased that British Columbia has now included Foquest on the BC PharmaCare Formulary to give physicians an additional choice for their ADHD patients who require public coverage," said Jodan Ratz, Country Medical Director at Elvium Life Sciences. "We thank the province for its decision which now means that all ADHD patients aged six years of age and older have equivalent access to Foquest should this be the right treatment for them." See the full Canadian Product Monograph for FOQUEST ® 12 The Product Monograph for FOQUEST ® contains a Serious Warning and Precaution for drug dependence, emphasizing that abuse of FOQUEST ® can lead to dependence. Healthcare professionals should assess the risk of abuse prior to prescribing FOQUEST ®, including in patients with a history of drug dependence or alcoholism, and monitor for signs of abuse and dependence while patients are on therapy. FOQUEST ® is a once-daily, long-acting methylphenidate controlled-release capsule for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients greater than or equal to six years of age. The maximum daily dose of FOQUEST ® for children and adolescents (6 to <18 years old) is 70mg, and the maximum daily dose for adults (≥18 years old) is 100 mg. Adverse events observed with FOQUEST ® treatment mainly reflect side effects commonly associated with methylphenidate use. Very common adverse events reported by patients treated with FOQUEST ® were headache, insomnia, decreased appetite and abdominal pain. Most of the events were mild to moderate in severity. About Elvium Life Sciences Elvium Life Sciences is an independent associated company of Purdue Pharma (Canada), that focuses on specialty pharmaceutical products committed to providing treatment options for patients who suffer from the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD) and products for ophthalmology. For more information, please visit
Global News
22-07-2025
- Global News
N.B. family says son with autism kicked out of ER for being loud, disruptive
The parents of a New Brunswick boy say they're angry after they were asked to leave a hospital emergency room because their son, who has ADHD and autism, was allegedly being too loud while he was waiting to be seen for seizures. Lorissa and Glendon Kingston had brought their seven-year-old son, Cayden, to the Saint John Regional Hospital's ER department on July 15. Cayden, who is non-verbal and has epilepsy, has struggled with seizures since birth and had been experiencing longer episodes in recent days. 'The absence seizures are a lot more worse than the normal ones he has where he's jolting. The absent ones can create issues … like brain damage,' his father, Glendon, explained. The family called their pediatrician's office and was advised to take Cayden to the Saint John Regional Hospital. Story continues below advertisement Lorissa says they were triaged by a nurse upon entering the ER and then told to wait in the children's RAZ (rapid assessment zone) waiting room. She recalls that after another patient left, she was alone with her son in that particular room. 'Then he started to get overwhelmed with all the seizures that he was having. So sometimes he vocal stims, and he'll have vocal outbursts where he just screeches and it's not really controllable,' Lorissa said. 'So he started having those and then the nurse come in and said, 'If he can't stop screaming, you guys will have to leave and you won't be welcome here because he's disrupting other patients.'' Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Lorissa says she explained to the nurse that her son can't control the stims. 'She's like, 'Well then, I guess I need you guys to leave.' So we ended up just getting up and leaving and then followed up with a doctor after.' The parents say it feels like their son was discriminated against and they're upset they're being forced to fight for health care for him. 'I never thought we would ever get kicked out of an emergency room while seeking care for him,' Lorissa said. Story continues below advertisement '(It) is basically a human right that you need medical help, you go, you get the help you need. And they turned him away. So, it was sad because they were discriminating against him for being different.' ER was at 206% capacity: Horizon Health In a statement to Global News, Horizon Health Network said that while it could not comment on the specifics of the case due to privacy laws, it wanted to 'express compassion to the child and their family during what was a distressing and difficult situation.' Pam Power, the clinical executive director of emergency medicine and critical care, said Horizon does not deny care to any patient in the ER and follows a standardized triage protocol. 'We aim to provide compassionate, inclusive care to all patients. This includes making efforts to accommodate patients who may be non-verbal, neurodivergent, or have other communication or behavioural challenges,' she wrote. 'Staff are encouraged to offer quieter spaces when available and to work with families and caregivers to understand and support the patient's unique needs.' The statement goes on to say that Saint John Regional Hospital, along with the other regional hospitals, has been facing significant 'capacity challenges.' 'On the date referenced, the ED inpatient occupancy at SJRH was at 206%,' she added. Story continues below advertisement Power encouraged anyone with concerns about their experiences to reach out to their patient relations department. Lorissa showed Global News a copy of an email she sent to that department on July 15, but said she hasn't received a reply. She adds that in the past, when they've sought medical care and Cayden was experiencing vocal stims, they were given a separate room but had never been denied care before. Meanwhile, the Kingston family hopes speaking out about their experience will enact change because ultimately, they know they have to keep going to the hospital's ER if Cayden needs medical attention. 'In the future, I know that I would bring him back if he had to go back but the thought is still going to be in my head: 'What if they kick us out again?'' Lorissa said. 'It will never be like, 'Oh yeah, I'm confident that he'll get the help he needs.' I just want the people who I've reached out to to do something because I know that they have the power to do it.'
